Clinical Trial Detail

NCT ID NCT03971461
Title Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NYU Langone Health
Indications

meningioma

Therapies

lutetium Lu 177 dotatate

Age Groups: adult senior

No variant requirements are available.